WS Audiology is the no. 1 applicant for patents within hearing aid industry

Hearing aid company WS Audiology takes first place in the top 30 of patent applicants in conventional hearing aid technology, according to new report. The company credits its concentrated patent strategy, and now, it will also increase its patent efforts in Asian markets.

WS Audiology Chief R& D Stefan Menzl | Photo: WS Audiology / PR

Danish hearing aid companies are world-leading in the global market for hearing devices, taking up a share of more than 60 percent in the global market, and WS Audiology, especially, contributes to Denmark's position in the global vanguard when it comes to the development of new hearing aid solutions, according to a recent 2021 report from the World Intellectual Property Organization (WIPO) which uses patent and other data from 1998 to 2019 to provide factual information on global innovation in assistive technologies.

In the 30 most active patent applications, Danish-domiciled WSA takes first place by far, measured by number of patent families within the category 'conventional hearing aid technology' in the last 21 years.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs